CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-18). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2878 · Search date 2026-08-18 · Methodology v0.7

Add-on oral roflumilast 500 mcg, a PDE4 inhibitor,
does it really help with Reduced moderate or severe exacerbations in severe COPD on maximal inhaled therapy?

30-Second Summary
D
Evidence Grade D · 30 · Safety caution
Oral add-on therapy did not significantly reduce the overall primary exacerbation rate
Adverse-event discontinuation was 11.7% versus 5.4%; diarrhea, nausea, and weight loss were more common. Prescription monitoring is required.
What the
research shows
The grade is D. Primary annual moderate/severe exacerbation rates were 1.17 versus 1.27 per patient-year, absolute difference -0.10, rate ratio 0.92 (95% CI 0.81 to 1.04), P=0.163. The prespecified significance threshold was missed, while the interval still allowed a 19% relative rate reduction.
What the
ads claim
A post hoc high-risk subgroup and lung-function improvement cannot convert the overall primary P=0.163 result into success.
*

Useful facts when choosing a product

  • Roflumilast is an oral selective PDE4 inhibitor.
  • Background therapy was ICS/LABA, with LAMA allowed.
  • Diarrhea, nausea, weight loss, and discontinuation require monitoring.
Gap Measurement · Verdict 2878 · D 30
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Moderate events required oral or parenteral glucocorticosteroids; severe events required hospitalization and/or led to death. Thus treatment decisions and hospitalization were combined.

Axis 6 B0 evidence ① Allocation concealment: randomized 1:1 through an interactive voice/web response system, stratified by LAMA use. ② Blinding: 'double-blind, placebo-controlled, parallel-group trial' with matching placebo. ③ Analysis set and missingness: 'Intent-to-Treat Study Population' analyzed by negative binomial regression with exposure time. ④ Prespecified primary endpoint: 'The primary efficacy measure is the rate of moderate or severe COPD exacerbations per participant per year' - consistent with NCT01443845.

Dropout candidate gates ① Defect: substantial attrition. ② Listed item: substantial attrition (at least 15%). ③ Evidence: 591/2,354=25.1% did not complete treatment. ④ Avoidability: not applicable; this was an ITT event-rate analysis using observed time, so fixed-time missingness requirements were not met.

02

Why this is classified as D (30)

P, R1, I0, E0, B0, and C0 yield D with 30 points.

Counterpoint. The post hoc very-frequent-exacerbator signal requires confirmation.

Rejudgment record. Cross-check applied — Used the null overall ITT event-rate analysis while preserving benefit allowed by the confidence interval and manufacturer-only evidence

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced exacerbations overallDRate ratio was 0.92 (0.81 to 1.04), P=0.163.
Improved lung functionCThe prespecified secondary result was favorable, but the primary exacerbation rate failed.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 152-week phase 4 multicenter randomized double-blind placebo-controlled add-on trial1,174Manufacturer support related to Takeda and AstraZeneca with company authors disclosedAnnual rate of moderate or severe COPD exacerbations1.17 versus 1.27 per patient-year; rate ratio 0.92 (95% CI 0.81 to 1.04), absolute difference -0.10, P=0.163.Pivotal manufacturer-funded null trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-18).

Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on COPD Exacerbations (RE(2)SPOND). Am J Respir Crit Care Med. 2016;194:559-567. PMID: 27585384. DOI: 10.1164/rccm.201607-1349OC.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none

Cite this verdict

No Benefit of Adding Oral Roflumilast for Exacerbations in Severe COPD on Maximal Inhaled Therapy Evidence Grade D card
[Chamgap] No Benefit of Adding Oral Roflumilast for Exacerbations in Severe COPD on Maximal Inhaled Therapy — Evidence Grade D·30. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/oral-roflumilast-maximal-inhaled-therapy-severe-copd-exacerbations/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.